Profiling of histamine H(4) receptor agonists in native human monocytes

par Gschwandtner, M, Koether, B, Werfel, T, Stark, H, Gutzmer, R
Publié 2013

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

par Satzger, I, Schaefer, T, Kuettler, U, Broecker, V, Voelker, B, Ostertag, H, Kapp, A, Gutzmer, R
Publié 2008

Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model

par Gschwandtner, M, Mildner, M, Mlitz, V, Gruber, F, Eckhart, L, Werfel, T, Gutzmer, R, Elias, P M, Tschachler, E
Publié 2013

Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?

par Ivanyi, P., Park-Simon, T., Christiansen, H., Gutzmer, R., Vogel, A., Heuser, M., Golpon, H., Hillemanns, P., Haier, J.
Publié dans Clin Exp Metastasis (2021)

Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells

par Pincha, M, Salguero, G, Wedekind, D, Sundarasetty, B S, Lin, A, Kasahara, N, Brugman, M H, Jirmo, A C, Modlich, U, Gutzmer, R, Büsche, G, Ganser, A, Stripecke, R
Publié 2011

Lentivirus-induced ‘Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma

par Sundarasetty, B S, Chan, L, Darling, D, Giunti, G, Farzaneh, F, Schenck, F, Naundorf, S, Kuehlcke, K, Ruggiero, E, Schmidt, M, von Kalle, C, Rothe, M, Hoon, D S B, Gerasch, L, Figueiredo, C, Koehl, U, Blasczyk, R, Gutzmer, R, Stripecke, R
Publié dans Gene Ther (2015)

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

par Dummer, R., Guminksi, A., Gutzmer, R., Lear, J.T., Lewis, K.D., Chang, A.L.S., Combemale, P., Dirix, L., Kaatz, M., Kudchadkar, R., Loquai, C., Plummer, R., Schulze, H.‐J., Stratigos, A.J., Trefzer, U., Squittieri, N., Migden, M.R.
Publié dans Br J Dermatol (2019)

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

par Lear, J.T., Migden, M.R., Lewis, K.D., Chang, A.L.S., Guminski, A., Gutzmer, R., Dirix, L., Combemale, P., Stratigos, A., Plummer, R., Castro, H., Yi, T., Mone, M., Zhou, J., Trefzer, U., Kaatz, M., Loquai, C., Kudchadkar, R., Sellami, D., Dummer, R.
Publié dans J Eur Acad Dermatol Venereol (2017)

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

par Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P.
Publié dans Ann Oncol (2016)

A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma

par O'Day, S, Pavlick, A, Loquai, C, Lawson, D, Gutzmer, R, Richards, J, Schadendorf, D, Thompson, J A, Gonzalez, R, Trefzer, U, Mohr, P, Ottensmeier, C, Chao, D, Zhong, B, de Boer, C J, Uhlar, C, Marshall, D, Gore, M E, Lang, Z, Hait, W, Ho, P
Publié 2011

Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma

par Schilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kähler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U., Schadendorf, D.
Publié dans Ann Oncol (2014)

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

par Hersh, E. M., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R., Haydon, A., Robert, C., Ernst, S., Homsi, J., Grob, J. J., Kendra, K., Agarwala, S. S., Li, M., Clawson, A., Brachmann, C., Karnoub, M., Elias, I., Renschler, M. F., Hauschild, A.
Publié dans Ann Oncol (2015)

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

par Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Publié dans ESMO Open (2016)